Hepatitis C in the setting of HIV co-infection.
Hepatitis C virus (HCV) co-infection is common among HIV-infected individuals and can lead to increased morbidity and mortality in this population. HIV adversely impacts the natural history of HCV disease with higher rates of liver disease progression but the effect of HCV on the natural history of HIV is disputed. Additionally, presence of HCV may decrease tolerability of highly active antiretroviral regimens for HIV treatment due to a potential increase in hepatotoxicity. Currently there is limited information available regarding HCV therapy in the setting of HIV co-infection but the HCV virologic response to interferon regimens appears to be similar to those individuals with HCV infection alone. However, additional information is required to assess the efficacy and safety of HCV therapy including possible interaction of HCV and HIV anti-viral medications in these co-infected individuals.
Khalili
Mandana
M
University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, NH-3D, San Francisco, CA 94110, USA. khalili@itsa.ucsf.edu
Behm
Brian W
BW
D000998:Antiviral Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*
D000998:Antiviral Agents; D007372:Interferons